{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:36:41Z","timestamp":1785447401138,"version":"3.56.0"},"reference-count":25,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Herpes zoster (HZ) poses significant risks to immunocompromised individuals, particularly cancer patients receiving systemic therapies. The recombinant zoster vaccine (RZV, Shingrix\u00ae) provides strong and durable protection against HZ and its complications. Nevertheless, vaccination coverage remains low, mainly due to limited awareness among patients and healthcare providers and logistical barriers to vaccine access and delivery. Materials and Methods: We conducted a single-center quality improvement (QI) project to enhance RZV uptake among oncology outpatients receiving systemic therapy. Following the Plan\u2013Do\u2013Study\u2013Act (PDSA) model, baseline HZ vaccination coverage was assessed, and an in-house vaccination campaign was implemented. Vaccination rates were monitored every two months over a 14-month period. Results: At baseline, only 5.4% (24\/446) of patients had received RZV. After 14 months, 365 patients were evaluated for vaccination: 200 (55%) were vaccinated, 134 (37%) were ineligible, and 31 (8%) refused RZV. The overall vaccination rate increased from 5.4% to 44%. Reported adverse events were mild and primarily local reactions, confirming the vaccine\u2019s favorable safety profile in this population. Conclusions: This real-world QI initiative demonstrates that an in-house vaccination strategy embedded within oncology services can substantially improve RZV coverage and patient engagement. The approach highlights the key role of oncology teams in leading preventive interventions for immunocompromised patients. By integrating vaccination into routine cancer care, institutions can overcome traditional organizational barriers and align with current ASCO and ESMO recommendations for comprehensive patient protection.<\/jats:p>","DOI":"10.3390\/cancers17213502","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:33:07Z","timestamp":1761881587000},"page":"3502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing Herpes Zoster Vaccination Rates Among Oncology Outpatients: Impact of an In-House Vaccination Initiative"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-7150","authenticated-orcid":false,"given":"Alberto Giuseppe","family":"Agostara","sequence":"first","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Della Torre","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Pelliccione","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Candido","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Smiroldo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Toniolo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zannier","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bollina","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale G. Salvini\u2014Rho\u2014ASST Rhodense, Rho, 20017 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2015.10.004","article-title":"Zeroing in on zoster: A tale of many disorders produced by one virus","volume":"358","author":"Galetta","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40257-019-00483-1","article-title":"Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review","volume":"21","author":"Rosamilia","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/jiy626","article-title":"Risk of Herpes Zoster in Cancer Patients and the Promise of New Vaccines","volume":"220","author":"Kawai","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: Population-based case\u2013control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"Vroling","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk Factors for Herpes Zoster Infection: A Meta-Analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kennedy, P.G.E., and Gershon, A.A. (2018). Clinical Features of Varicella-Zoster Virus Infection. Viruses, 10.","DOI":"10.3390\/v10110609"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/cncr.32926","article-title":"Radiation therapy and the risk of herpes zoster in patients with cancer","volume":"126","author":"Shimizuguchi","year":"2020","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/PL00002318","article-title":"Herpes zoster in breast cancer patients after radiotherapy","volume":"176","author":"Dunst","year":"2000","journal-title":"Strahlenther. Onkol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/imt-2021-0333","article-title":"Herpes Zoster in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors","volume":"14","author":"Serra","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.jtho.2019.02.033","article-title":"Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer","volume":"14","author":"Watanabe","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/1759-7714.13377","article-title":"Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report","volume":"11","author":"Gozzi","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_14","unstructured":"SHINGRIX (2024, July 02). FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix."},{"key":"ref_15","unstructured":"Strezova, A., D\u00edez-Domingo, J., Tinoco, J.C., Leon, R., Soni, J., Tsang, M., and Mwakingwe-Omar, A. (2024, January 27\u201330). Adjuvanted recombinant zoster vaccine (RZV) is the first vaccine to provide durable protection against herpes zoster (HZ) in all age ranges \u226550 years: Final analysis of efficacy and safety after 11 years (Y) of follow-up. Proceedings of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Barcelona, Spain."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/infdis\/jiaa300","article-title":"Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination","volume":"224","author":"Hastie","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100548","DOI":"10.1016\/j.esmoop.2022.100548","article-title":"Vaccination for herpes zoster in patients with solid tumors: A position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)","volume":"7","author":"Pedrazzoli","year":"2022","journal-title":"ESMO Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults With Cancer: ASCO Guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12879-024-09344-7","article-title":"Herpes zoster (HZ) vaccine coverage and confidence in Italy: A Nationwide cross-sectional study, the OBVIOUS project","volume":"24","author":"Salussolia","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kiderlen, T.R., Trostdorf, K., Delmastro, N., Salomon, A., de Wit, M., and Reinwald, M. (2022). Herpes Zoster Vaccination Rates in Hematological and Oncological Patients\u2014Stock Taking 2 Years after Market Approval. Healthcare, 10.","DOI":"10.3390\/healthcare10081524"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2217\/cer-2020-0251","article-title":"Patterns and association of vaccination among adults with a history of cancer in the USA: A population-based study","volume":"10","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107680","DOI":"10.1016\/j.pec.2023.107680","article-title":"Vaccine hesitancy in cancer patients: A rapid review","volume":"111","author":"Butow","year":"2023","journal-title":"Patient Educ. Couns."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/JHQ.0000000000000422","article-title":"Quality Improvement Interventions to Enhance Vaccine Uptake in Cancer Patients: A Systematic Review","volume":"46","author":"Kazi","year":"2024","journal-title":"J. Healthc. Qual. JHQ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S957","DOI":"10.1016\/j.annonc.2024.08.1650","article-title":"1588P Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience","volume":"35","author":"Bella","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:49:37Z","timestamp":1762181377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":25,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213502"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213502","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}